SCHEMBL30186375

SCHEMBL30186375

Oc1cccc(-c2ccc3nccn3c2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.57
HSD17B2 P37059 6/20 0.48
HSD17B1 P14061 5/20 0.48
CYP3A4 P08684 3/20 0.48
CYP2C9 P11712 2/20 0.48
TGFBR1 P36897 3/20 0.48
TGFBR2 P37173 1/20 0.48
RET P07949 3/20 0.46
PIK3CA P42336 2/20 0.45
PIK3R1 P27986 1/20 0.45
FAAH O00519 1/20 0.44
ESR1 P03372 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2B6 P20813 1/20 0.42
CYP2C19 P33261 1/20 0.42
ESR2 Q92731 1/20 0.42
CYP17A1 P05093 1/20 0.42
CYP19A1 P11511 1/20 0.42
CYP11B1 P15538 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31381049 0.82 DYRK1A (0.71) DYRK1ATGFBR1TGFBR2RETPIK3CA
SCHEMBL13680666 0.81 TGFBR1 (0.68) DYRK1ACYP3A4TGFBR1TGFBR2RET
SCHEMBL1832251 0.81 DYRK1A (0.57) DYRK1ATGFBR1TGFBR2RETPIK3CA
SCHEMBL30007309 0.81 DYRK1A (0.63) DYRK1ACYP3A4TGFBR1TGFBR2RET
SCHEMBL14320819 0.81 DYRK1A (0.63) DYRK1ACYP3A4TGFBR1TGFBR2RET
SCHEMBL30186393 0.81 HSD17B2 (0.47) HSD17B2HSD17B1CYP3A4CYP2C9PIK3CA
SCHEMBL1576521 0.80 DYRK1A (0.73) DYRK1ATGFBR1TGFBR2RETPIK3CA
SCHEMBL14826052 0.79 DYRK1A (0.85) DYRK1ACYP3A4TGFBR1TGFBR2RET
SCHEMBL24529594 0.79 RET (0.61) DYRK1ATGFBR1TGFBR2RETFYN
SCHEMBL20004011 0.78 ALDH1A3 (0.60) DYRK1ACYP3A4TGFBR1TGFBR2FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522597-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2026-01-13 US disclosed
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 DYRK1A 4465/4885HSD17B2 2758/4885HSD17B1 2342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.